Avirmax, Inc.

Avirmax, Inc. is a San Francisco Bay Area-based startup dedicated to innovating and manufacturing adeno-associated virus (AAV) vector mediated biotherapeutics. Utilizing its proprietary protein therapeutics and BAC-to-AAV technologies, Avirmax aims to deliver safe, effective, long-acting AAV-mediated biotherapeutics in an accessible and affordable manner. The company's Avirmax Adeno-associated Vector Innovation Platform (AAVIP) facilitates the production of highly infectious AAV vectors with high titers, ensuring enhanced expression of the gene of interest (GOI) in target cells. Founded in 2019, Avirmax is committed to addressing challenges in viral vector production through its state-of-the-art AAV bioprocess technologies and Virovek’s BAC-to-AAV insect system. By establishing robust rAAV vector production technologies for small and large-scale applications, Avirmax, Inc. is poised to make significant contributions to the field of gene therapy.